9 Meters Biopharma is a clinical-stage company focusing on the treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. Co. is deveoping its primary product candidate, vurolenatide for the treatment of SBS, as well as NM-136 for rare obesity disorders. Co. is also developing NM-003 and NM-102 for the treatment of undisclosed rare debilitating digestive diseases with unmet needs and larazotide for the treatment of Multi-system Inflammatory Syndrome through a collaboration with the European Biomedical Research Institute of Salerno, Italy. The NMTR average annual return since 2016 is shown above.
The Average Annual Return on the NMTR average annual return since 2016 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether NMTR average annual return since 2016 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NMTR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free NMTR Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
